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Abstract
Background: One of the most distinctive features of ankylosing spondylitis (AS) is new bone formation and bone
resorption at sites of chronic inflammation. Previous studies have indicated that the hyperplasia and inflammation
of synovial tissues are significantly related to the pathogenic process of AS. The present study used a proteomic
approach to identify novel AS-specific proteins by simultaneously comparing the expression profiles of synovial
membranes from patients with AS, rheumatoid arthritis (RA) and osteoarthritis (OA).
Methods: Synovial tissues were collected from the hip joints of patients with AS and knee joints of patients with
RA or OA (n = 10 for each disease) during joint replacement surgery. Proteins extracted from the synovial tissues
were separated by 2-D electrophoresis (2-DE), and the proteins with significantly increased expression in the AS
samples were subjected to MALDI-TOF/TOF-MS analysis. The results were verified using western blotting and
immunohistochemistry. Levels of the candidate proteins in synovial fluids from knee joints (n = 40 for each
disease) were measured using ELISA.
Results: The proteomic approach revealed significantly increased expression of carbonic anhydrase I (CA1) in the
synovial membrane of patients with AS as compared with the RA and OA tissue samples. Immunohistochemistry
and western blotting analysis confirmed the findings described above. The ELISA detected a higher level of CA1 in
synovial fluids from patients with AS than those with OA. The mean value of the CA1 level was also higher in AS
patients as compared with RA patients. This study also detected increased expression of alpha-1-antitrypsin in the
synovial tissues from AS patients, which is in agreement with other reports.
Conclusion: In vitro experiments by other groups indicated that CA1 catalyzes the generation of HCO3
- through
the hydration of CO2, which then combines with Ca
2+ to form a CaCO3 precipitate. Calcification is an essential step
of bone formation. Substantial evidence indicates that carbonic anhydrase also stimulates bone resorption. Hence,
overexpression of CA1 in the synovial tissues of AS patients may promote improper calcification and bone
resorption in AS.
Background
Ankylosing spondylitis (AS) is a chronic inflammatory
disease that can cause significant complications by
affecting the sacroiliac joints and axial skeleton. AS is
characterized by two key pathologic features: sacroiliac
joint and spinal inflammation and new bone formation
with possible bone fusion, usually in the axial skeleton
[1,2]. However, the pathologic mechanism of AS, espe-
cially the molecular mechanism of ossification, remains
largely unclear. Histopathological experiments demon-
strated that severe forms of AS significantly correlate
with villous chronic synovitis, including obliterating vas-
cularitis, fibrosclerosis, necrosis and calcification of dis-
integrated synovial structures [3]. The global disease
activity of AS significantly correlates with hyperplasia of
the synovial membrane as well as with inflammatory
infiltration of macrophages, especially the CD163+
subset, and polymorphonuclear leukocytes [4]. These
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vium of patients with AS are closely related to disease
progression.
Proteomics is a powerful new tool for rheumatology
research. Using this approach, Liu et al. demonstrated
high expression of the haptoglobin precursor in the sera
of patients with AS [5]. Write et al. detected upregula-
tion of the beta subunit of the proteasome activator
PA28 in AS monocytes [6]. In the present study, we per-
formed a proteomic analysis of AS synovial membranes
and compared the expression profile with profiles from
rheumatoid arthritis (RA) and osteoarthritis (OA) syno-
vial membranes. AS has some similar symptoms to RA
and was clinically classified as RA many years ago [7].
OA is arthritic disease involving the degradation of
joints including articular cartilage and the adjacent sub-
chondral bone. Therefore, comparing the expression
profiles of these three diseases could effectively filter out
inflammatory proteins and metabolism-related proteins
to discover protein biomarkers that are specific to AS.
Methods
Patients and sample collection
Synovial tissues were collected during joint replacement
surgery from patients with AS (n = 10, 3 female; 24-54
years old, mean 34), RA (n = 10, 8 female; 30-65 years
old, mean 51) and OA (n = 10, 4 female; 40-72 years
old, mean 62). The AS tissues were collected from the
hip joints of patients, and the RA and OA tissues were
c o l l e c t e df r o mt h ek n e ej o i n t so fp a t i e n t s .T h es a m p l e s
were dissected from the connective tissues and immedi-
ately stored at -80°C until use. AS patients had an aver-
age disease duration of 7 years and were positive for the
HLA-B27 antigen. Their symptoms fulfilled the modified
New York criteria for AS [8]. The diagnosis of RA ful-
filled the American College of Rheumatology criteria.
The patients with RA had disease durations of 3 to 10
years and were classified as having erosive RA (Larsen
class IV-V). They had high levels of C-reactive protein
(6-192 mg/liter, mean 70 mg/liter), anti-CCP (92-394 U/
ml) and RF (78-1280 U/ml). Patients with AS and RA
took disease-modifying antirheumatic drugs (DMARDs)
before surgery. Patients with AS, RA and OA were also
medicated with non-steroidal anti-inflammatory drugs
(NSAIDs), which help reduce the pain and swelling of
the joints and decrease stiffness. Table 1 summarizes
the epidemiological data.
Synovial fluids were aspirated from the joints of patients
with AS (n = 40, 12 females; 26-54 years old, mean 35),
RA (n = 40, 30 females; 23-73 years old, mean 44) and
OA (n = 40, 16 females; 47-86 years old, mean 61).
Patients with AS had disease durations of 3 to 8 years.
Patients with RA had disease d u r a t i o n so f3t o1 0y e a r s .
Patients with OA had disease durations of 3 to 13
years. The diagnosis is described above. They were medi-
cated with NSAIDs and DMARDs.
All patients provided informed consent, and the study
protocol was approved by the Ethics Committee of the
Shandong Academy of Medical Sciences.
2-DE, protein spot collection and MALDI-TOF/TOF-MS
analyses
Synovial tissues were homogenized and added to lysis
buffer (7 M Urea, 2 M thiourea, 4% CHAPS, 2% IPG
buffer, 65 mM DTT, 1 mM PMSF and Protease Inhibi-
tor Cocktail). The extracted proteins were purified with
a 2-D Clean-Up Kit (GE Healthcare), which improves
the quality of 2-D electrophoresis results by removing
interfering contaminants. The concentrations of the pro-
tein samples were determined with the 2-D Quant Kit
(GE Healthcare). Cell lysates from AS, RA and OA
synovial tissues with equal protein content were pooled.
Isoelectric focusing (IEF) was applied to 24-cm IPG
strips (pH 3-10 NL; GE Healthcare) using an Ettan IPG-
phor II IEF system (GE Healthcare). One hundred
microgram of the protein sample was applied on IPG
strips. After equilibration, the second dimension was
performed on 12.5% SDS-polyacrylamide gels at a con-
sistent power supply (with initial separation at a con-
stant 0.2 w/gel for 1 hour followed by 17 w/gel at 25°C).
The proteins were then stained with Coomassie Blue
R350 (GE Healthcare) and scanned using a PowerLook
2100 XL scanner system (Umax). Gel images were ana-
lyzed with the Imagemaster 5.0 software package (GE
Healthcare), and the spots with a 3-fold intensity change
were excised from the gels for MALDI-TOF/TOF-MS
analysis.
Gel spot pieces were destained in 50 mM ammonium
bicarbonate/50% acetonitrile (ACN) buffer, dehydrated
in 100% ACN for 15 minutes, and then dried by
vacuum centrifugation. The dried pieces were added to
modified trypsin buffer (Promega) (10 ng/μli n2 5m M
NH4HCO3, pH 8.0) and incubated overnight at 37°C.
Peptides were extracted with 5% trifluoroacetic acid
(TFA)/50% ACN (v/v). After vacuum centrifugation,
the lyophilized extract was redissolved in 0.1% TFA/
30% ACN (v/v). Extracted peptides were mixed with
an equal volume of a-cyano-4-hydroxycinamic acid
matrix (a-CHCA) matrix (Sigma) and then spotted
onto a standard 192-well plate for mass spectrometry
analysis using an ABI 4700 Proteomics Analyzer
MALDI-TOF/TOF mass spectrometer (ABI). Peptide
mass fingerprinting (PMF) was acquired in a reflective
mode, and at least two matched peaks were further
validated by TOF-TOF analysis. The spectra data were
searched against a human subset of the Swiss-Prot
database for protein identifications using GPS explorer
software.
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Two hundred micrograms of each sample from synovial
tissues (n = 5 for each diseases) were homogenized in
Cell Lysis Solution (Sigma) and centrifuged at 16,000 ×
g for 5 min at 4°C. The supernatant was collected after
centrifugation, and the protein concentration was deter-
mined using the BCA protein assay kit (Pierce). Five
micrograms of total protein were loaded and separated
by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE), transferred onto nylon mem-
branes and probed with anti-human carbonic anhydrase
I (CA1) antibody (Abcam, USA). The antibody was pre-
pared by immunizing a goat with carbonic anhydrase I
extracted from human erythrocytes. The manufacturer
confirmed no cross-reactivity with other carbonic anhy-
drases. Immunoreactive signals were detected with alka-
line phosphatase-conjugated secondary antibodies and
visualized using a western Blotting Luminol Reagent
(Amersham). Images of western blots were acquired on
a Typhoon Trio (GE Healthcare). The quantification
was conducted using ImageQuant5.2 software. Another
membrane was prepared using the same protocol and
probed with anti-GADPH antibody (Santa Cruz) to nor-
malize for sample loading.
Immunohistochemistry
Synovial tissues (n = 10 for each diseases) were fixed in
10% neutral buffered formalin for 12 hours at room
temperature, embedded in paraffin and sectioned using
standard procedures. Tissue sections were deparaffinized
and rehydrated using standard procedures. To increase
immunostaining intensity, the sections were heated at
95°C for 10 min in citrate buffer (0.01 M, pH 6.0). Sec-
tions were incubated with the primary antibody over-
night at 4°C. Following incubation, tissue sections were
washed three times for three minutes each in PBS and
Table 1 Clinical data on patients with AS, RA and OA
Diagnosis Patient No. Sex Age
(years)
HLA-B27 RF anti-CCP
U/ml
ESR
(mm.h-1)
CRP
(mg.dL-1)
Disease duration
(years)
NSAIDs DMARDs
AS 1 male 35 + - - 46 34 3 yes yes
AS 2 male 29 + - - 7 6 12 yes yes
AS 3 male 24 + - - 16 6 5 yes yes
AS 4 male 31 + - - 45 6 6 yes yes
AS 5 male 36 + - - 40 6 6 yes yes
AS 6 male 37 + - - 24 5 8 yes yes
AS 7 male 13 + - - 62 8 7 yes yes
AS 8 female 48 + - - 58 10 5 yes yes
AS 9 female 28 + - - 10 6 10 yes yes
AS 10 female 54 + - - 12 6 10 yes yes
RA 11 female 30 ND 100 209 80 6 4 yes yes
RA 12 female 58 ND 160 279 72 192 9 yes yes
RA 13 female 65 ND 496 218 66 153 7 yes yes
RA 14 female 41 ND 78 168 39 10 3 yes yes
RA 15 female 64 ND 200 169 61 10 5 yes yes
RA 16 male 53 ND 107 171 55 20 3 yes yes
RA 17 female 49 ND 160 227 50 96 4 yes yes
RA 18 male 50 ND 1280 394 84 153 6 yes yes
RA 19 female 53 ND 599 171 31 6 7 yes yes
RA 20 female 48 ND 107 92 13 60 10 yes yes
OA 21 male 40 ND - ND 10 6 6 yes -
OA 22 female 62 ND - ND 68 48 10 yes -
OA 23 female 53 ND - ND 20 6 8 yes -
OA 24 female 60 ND - ND 22 6 8 yes -
OA 25 male 66 ND - ND 24 10 6 yes -
OA 26 female 72 ND - ND 24 6 5 yes -
OA 27 male 65 ND - ND 5 10 11 yes -
OA 28 male 72 ND - ND 8 6 13 yes -
OA 29 male 68 ND - ND 24 6 7 yes -
OA 30 male 67 ND - ND 10 20 6 yes -
ND: no data available
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(Maixin-Bio, China) according to the manufacturer’s
instructions. Immunoreactive signals were visualized
using the DAB substrate, which stains the target protein
a brown color. Tissue structure of the section was
defined by counterstaining with hematoxylin.
ELISA
The fluid samples were centrifuged at 3,000 × g for 10
min at 4°C to remove debris. Fluid samples were diluted
20-fold with 0.05 M carbonate-bicarbonate buffer (pH
9.6) and were used to coat 96-well ELISA microplates
(Costar) by overnight incubation at 4°C. After a brief
wash with PBS containing 0.1% Tween 20 (PBST), the
plates were blocked with 5% non-fat dry milk for 1 hour
at room temperature. The anti-CA1 antibody was
diluted 1,000-fold with PBST, added to the plate, and
incubated for 2 hours at room temperature. After wash-
ing with PBST, the plate was incubated with a 10,000-
fold dilution of anti-goat IgG alkaline phosphatase-con-
jugated antibody (Sigma) for 30 min at room tempera-
ture. Following a wash with PBST, the signal was
developed by adding Alkaline Phosphatase Yellow
(pNPP) Liquid Substrate System For ELISA (Sigma).
The absorbance of the reaction was measured at 405
nm with a plate reader (Synergy HT, Bio-Tek).
Statistical analysis of the data was performed using
SPSS V.16 software (SPSS, USA). Median differences
were tested with the Mann-Whitney U test. P values of
less than 0.05 were considered significant. When three
groups were compared, a Kruskal-Wallis test was con-
ducted first.
Results
Expression of CA1 in synovial membranes
In the current study, comparative 2-DE was used to dif-
ferentiate protein expression levels between the synovial
membranes from AS and RA patients and AS and OA
patients on a global scale. The experimental 2-DE gel
patterns were highly reproducible over the three experi-
ments. Following computational analysis, approximately
300 spots were visualized on each 2-DE gel. A 2-DE gel
prepared with AS samples is shown in Figure 1. Two of
the spots (#5 and #7) demonstrated 3-fold higher
expression in the AS sample as compared with the RA
and OA controls (Figure 2). Using MALDI-TOF MS,
the spots with increased expression in AS synovial tis-
sues were identified as carbonic anhydrase I (CA1) and
alpha-1-antitrypsin precursor (A1AT). The detailed
information about these identified proteins is shown
in Table 2. By comparing the expression profiles of
AS synovial membranes with those of RA, five other
protein spots were detected with more than 3-fold
greater expression. These proteins were identified as
serotransferrin precursor, hemopexin precursor, apolipo-
protein A-I precursor, dedicator of cytokinesis protein 2
and intersectin 1. By comparing the expression profiles
of AS synovial membranes with those of OA, 11 protein
spots were detected with more than 3-fold greater
expression. These proteins were identified as Ig gamma-
1 chain C region, dynein heavy chain, fibrinogen gamma
chain precursor, catalase, SH3 and multiple ankyrin
repeat domains protein 2, haptoglobin precursor, DNA-
dependent protein kinase catalytic subunit, apolipopro-
tein A-I precursor, serotransferrin precursor, microtu-
bule-actin crosslinking factor 1 isoform 4, and
intersectin 1. However, these proteins were also
expressed at increased levels in the synovial tissues of
RA patients or in the synovial tissues of OA patients,
and they were not specifically expressed at significantly
increased levels in the synovial tissues of AS patients.
Any differentially expressed spots demonstrating a less
than 3-fold change were not addressed in the present
study.
Western blot analysis was performed with antibodies
against CA1. Using GADPH as a reference, CA1 showed
significantly higher levels of expression in the synovial
membranes of AS patients than in samples from RA
and OA patients. The high level of expression was
observed in all of five synovial membranes tested.
Among the five OA synovial samples, only one sample
had a relatively high CA1 expression. All of the RA
synovial samples showed low levels of expression (Figure
3A and 3B). A similar result was also obtained using b-
actin as a reference.
Immunohistochemistry detected CA1 expression in all
AS synovial tissues (100%) and yielded high intensity
signals. The CA1 immunosignal was observed in the lin-
ing layer, the endothelial cells around the small blood
vessel and some fibroblast-like cells in the synovial
membranes of AS patients. On the other hand, CA1 was
detected in the thick lining layer of four samples of
synovial membranes from RA patients (40%), but the
signal intensity was relatively low and appeared as a
smear. CA1 was detected in six samples of synovial
membranes from OA patients (60%); the enzyme was
detected in the upper lining within the thin layer of
cells. The tissue distribution of CA1 is shown in Figure
4. The result is in agreement with the western blot
analysis.
Expression of CA1 in synovial fluid
ELISA was used to measure the levels of CA1 in the
synovial fluids from patients with AS, RA and OA at the
chronic inflammation stage. CA1 levels were signifi-
cantly elevated in AS fluids as compared with the OA
samples (p = 0.032). Compared to the average level of
the OA samples, fluid samples from AS patients had a
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samples (77.5%). Thirty-five of the AS samples (87.5%)
had relatively high levels of CA1 (O.D. > 2.0). This level
did not significantly change among OA samples, and
only two OA samples had higher levels of CA1 (O.D. >
2.0). Among the 40 RA synovial fluid samples, 12 sam-
ples had higher levels of CA1 (30%, O.D. > 2.0). The
mean levels of CA1 were higher in AS fluids than in RA
fluids, although there was no statistically significant
difference (p = 0.056). The ELISA result is shown in
Figure 5.
Discussion
In the present study, a proteomic approach exclusively
identified the increased expression of CA1 in AS synovial
membranes as compared with RA and OA samples. The
increased expression of CA1 was confirmed by individu-
ally investigating synovial samples from each disease
using western blot analysis. Immunohistochemistry also
located CA1 in the AS synovial membranes with a strong
signal density. Furthermore, the ELISA detected higher
levels of CA1 in the synovial fluid from patients with AS
compared to the OA samples. The mean value of the
CA1 level is also higher in AS patients as compared to
RA patients. The CA1 in the synovial fluid may be
secreted by the AS synovial membranes.
Samples for each disease condition were pooled for
2-DE proteomics, which is regarded as the best practice in
many studies to effectively find common features of dis-
eased tissues under variable conditions. Under normal cir-
cumstances, proteomic research conducts a comparison of
tissue samples from the two diseases, and it can conse-
quently obtain many protein spots with specific expres-
sions. In our study, we simultaneously compared the
samples from three arthritic diseases, and we therefore
obtained fewer but unique for the disease. Additionally, a
significantly increased expression level of the alpha-1-anti-
trypsin (A1AT) precursor, which is an important plasma
Figure 1 Two-dimensional polyacrylamide gel electrophoresis of the total protein extracted from the synovial tissues of AS patients.
Protein was visualized by staining with colloidal Coomassie Blue. Protein spots indicated by numbers (#5 and #7) were identified by MALDI-TOF
MS.
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tissues of AS patients using a proteomic approach. Some
reports have demonstrated the involvement of A1AT in
the pathogenesis of AS. Increased levels of the complex of
immunoglobulin with A-alpha 1 antitrypsin have been
detected in the serum of AS patients and were associated
with a clinical index of the disease [9,10]. Identifying
A1AT in the synovial membrane of AS patients confirmed
the feasibility and reliability of our protocol.
Tilleman et al. investigated the cytosolic proteome of
inflamed synovial tissue and validated the feasibility of
this proteomic analysis by identifying proteins that were
Figure 2 Comparison of the AS, RA and OA synovial proteins indicated by numbers in Figure 1. Protein spots (#5 and #7) from the AS
synovial tissue had 3-fold higher expression levels than the matched spots from RA and OA synovium.
Table 2 Identification of spots with significant over-expression in AS synovial membrane by proteome analysis
spot protein name MW(kDa.)
theoretical
pl
theoretical
Peptide
count
Protein
score
Intensity matched
%
protein species score C.
I.%
#5 carbonic anhydrase 1 28778.4 6.63 9 135 80.75 100
#7 alpha-1-antitrypsin
precursor
46878.1 5.37 10 133 84.79 100
MW, molecular weight; pl, isoelectric point.
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collected synovial biopsy samples from 18 patients under-
going needle arthroscopy for knee synovitis associated
with AS (n = 6) and RA (n = 6) and for joint effusion of
the knee associated with OA (n = 6). Following 2-DE, pro-
tein expression patterns were statistically analyzed and
used for hierarchical cluster analysis. Proteins of interest
were identified by matrix-assisted laser desorption/
Figure 3 Western blot analysis of CA1 expression in synovial membranes from AS, RA and OA patients. (A) Western blotting of CA1 in
AS, RA and OA synovial tissues (n = 5 for each disease). The molecular weight is indicated with arrows. Sample loading was normalized using
GADPH. (B) The CA1 signal was normalized to the GADPH signal. The expression levels are expressed as the mean ± SEM. CA1 was expressed at
a significantly higher level in AS synovial tissue than in RA and OA synovial tissues.
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Page 7 of 11Figure 4 Immunodetection of CA1 in the synovial membranes of AS, RA and OA patients. CA1 was significantly detected with a strong
immunosignal in AS synovial tissue. Original magnification: 100X and 200X. The picture at the bottom is a negative control prepared with AS
synovial tissue that was not treated with primary antibody.
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Page 8 of 11ionization- and electrospray ionization-mass spectrometry.
By identifying proteins that were differentially expressed
between AS and RA and AS and OA (P < 0.01), they
finally detected higher expression of fructose bisphosphate
aldolase A and alpha-enolase in AS synovial tissues than
in OA synovial tissues. They also detected a higher level of
calgranulin A myeloid-related protein-8 in the RA and AS
samples than in the OA samples [11]. In our study, we
conducted a proteomic analysis with whole synovial mem-
branes of hip joints from AS patients as opposed to syno-
vial biopsy samples taken by needle arthroscopy from the
knee joint of the patients. Additionally, we identified novel
AS-specific proteins by simultaneously comparing the
expression profiles of synovial membranes from patients
w i t hA S ,R Aa n dO A .W et h u sd e t e c t e de s p e c i a l l yh i g h
expression of CA1 in the synovial tissues of AS patients.
Because our patients and their patients all received treat-
ment with NSAIDs and DMARDs before surgery, the
medical treatment could not contribute to the differences
in the findings of our study and their study.
CA1 catalyzes the hydration of carbon dioxide and
forms bicarbonate [12]. Carbonic anhydrases (CA) parti-
cipate in the physiological and pathological activities of
calcification and mineralization [13]. Parissa et al. inves-
tigated the effect of CA1 on the hydration of CO2 and
the formation of calcium carbonate. They conducted an
in vitro assay using a reaction mixture containing bovine
CA1 and calcium chloride in Tris buffer. After CO2 was
added, CA1 enhanced the hydration reaction, and the
hydration reaction rate increased with both the enzyme
concentration and temperature. Furthermore, they
found that CA1 promotes the formation of CaCO3 and
the precipitant quickly settles [14]. Ramana et al. also
detected CaCO3 deposition in a calcium chloride solu-
tion saturated with CO2 in the presence of carbonic
anhydrase purified from Citrobacter freundii.T h e y
observed a sharp decrease in CaCO3 formation with the
addition of EDTA and acetazolamide, inhibitors of car-
bonic anhydrase [15]. These results indicated that CA1
not only enhances the hydration reaction of CO2,b u ti t
Figure 5 Detection of CA1 level in synovial fluids by ELISA. Levels are represented as O.D. values obtained from the absorbance at 405 nm.
The results are expressed as the mean ± SEM. Expression of CA1 was higher in AS samples than in OA samples.
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cium to form the solid precipitant of calcium carbonate.
Therefore, overexpression of CA1 in the synovium of
AS patients may lead to CaCO3 deposition in diseased
tissues. One of the most distinctive features of AS is
new bone formation at sites of chronic inflammation
[2]. Bone is mainly composed of calcium phosphate and
calcium carbonate [16]. In the physiological milieu, a
counterbalancing inhibition is required to prevent inap-
propriate formation of insoluble crystals of calcium salt
[17,18]. Increased CA1 expression in the synovium of
AS patients may lead to improper mineralization by
accelerating calcium salt deposition.
Increased bone resorption is a characteristic of AS
[19,20]. Using an in vitro neonatal mouse calvarial cul-
ture system, Hall et al. found that carbonic anhydrase
activity enhanced the stimulation of prostaglandin E2 for
resorption, which indicates that carbonic anhydrase is a
necessary component of the osteoclastic bone resorptive
mechanism [21]. Two years later, the group found that
the carbonic anhydrase inhibitor acetazolamide inhibited
bone resorption [22]. Nolan et al. also found that carbo-
nic anhydrase inhibitors including acetazolamide, ethox-
zolamide, methazolamide, and dichlorphenamide
reduced paw edema and attenuated joint deterioration
in rats with adjuvant arthritis. They suggested that the
carbonic anhydrase inhibitors played an antiarthritic
role by inhibiting bone resorption [23]. These investiga-
tions demonstrated a functional role for carbonic anhy-
drase in the mediation of hormone-stimulated bone
resorption [24]. Overexpression of CA1 in the synovium
of AS patients may be involved in bone resorption of
the disease. Additionally, studies have shown a high
incidence of uveitis in patients with AS, and approxi-
mately 40% of patients with uveitis are also HLA-B27
positive [25,26]. Acetazolamide, inhibitor of CA1, is
often used for the medical treatment of uveitis [27]. The
high expression levels of CA1 in the synovial tissues of
patients with AS may partially explain the strong asso-
ciation of the two diseases.
Most studies on AS focus on bone and bone develop-
ment of the disease, although some studies had demon-
strated that the global disease activity of AS significantly
correlates with hyperplasia of the synovial membrane.
Our results suggest that elevated expression of CA1 in
the diseased synovial tissues plays a role in new bone
formation and bone resorption. However, the impor-
tance of CA1 in AS processes is still unknown.
Conclusions
The current study detected increased expression of
CA1 in the synovial tissue of AS patients. It has been
demonstrated that CA1 can lead to CaCO3 precipitants.
Substantial evidence has indicated that carbonic anhy-
drase is also involved in bone resorption. These results
suggest that the overexpression of CA1 in the synovium
of AS patients may accelerate calcification and bone
resorption, which are two essential processes for new
bone formation. This finding may be helpful in under-
standing the pathogenic mechanism of AS.
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